Phathom Pharmaceuticals, Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated product revenue of $74.3 million for the three months ended June 30, 2026, a 88% increase from $39.5 million in the same period last year. For the six months ending June 30, 2026, total product revenue reached $132.6 million, compared to $68.0 million for the same period in 2025. The increase in revenue is attributed to the successful commercialization of its VOQUEZNA product line, which includes treatments for erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori infections.
Despite the revenue growth, Phathom reported a net loss of $17.6 million for the second quarter of 2026, a significant reduction from a net loss of $75.8 million in the same quarter of 2025. For the first half of 2026, the net loss was $48.0 million, down from $170.1 million in the prior year. The company’s operating expenses also decreased, with total operating expenses for the second quarter falling to $63.1 million from $94.4 million a year earlier, primarily due to reduced selling, general, and administrative costs.
Phathom's operational metrics indicate a successful market entry for its products, with approximately 1.7 million prescriptions filled for VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK since their launch in late 2023. The company has achieved broad commercial coverage, with access for over 120 million U.S. commercial lives. The company’s workforce was reduced by 6% in May 2025 as part of a restructuring plan aimed at reducing cash burn and focusing on commercial execution.
In terms of liquidity, Phathom reported cash and cash equivalents of $182.5 million as of June 30, 2026, an increase from $130.0 million at the end of 2025. The company believes its existing cash, along with anticipated product revenues, will be sufficient to fund operations for at least the next twelve months. However, it acknowledged the potential need for additional funding depending on future operational performance and market conditions. The company has also entered into various financing agreements, including a recent $175 million term loan, to support its operations and growth strategy.
Looking ahead, Phathom plans to continue its focus on the commercialization of its VOQUEZNA products while exploring additional opportunities for growth, including potential expansions into European and Canadian markets. The company is also actively pursuing life-cycle management opportunities for vonoprazan, its primary active ingredient, and is preparing for upcoming clinical trials, including a Phase 2 study for eosinophilic esophagitis.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals develops and commercializes novel gastrointestinal treatments, primarily focusing on vonoprazan, a potent, fast-acting potassium-competitive acid blocker. Its core products target acid-related GI diseases such as GERD and H. pylori infection. The company emphasizes innovative therapies with improved efficacy over traditional PPIs, leveraging a differentiated mechanism of action, and aims to expand indications and formulations in the U.S. and international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov